LL-37 vs Enfuvirtide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
LL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.
Also: Fuzeon, T-20
Enfuvirtide (brand name Fuzeon, originally T-20) is a 36-amino-acid synthetic peptide and the first HIV fusion inhibitor, FDA-approved in March 2003. It is a genuine prescription antiretroviral, not a research-only compound, and it is given as a twice-daily subcutaneous injection. Its job is narrow but important: it blocks HIV from entering a host cell in the first place, and it is reserved for people whose virus has stopped responding to other drugs.
Key Comparison Insights
- Enfuvirtide is FDA approved, while LL-37 remains in research stages.
- Both peptides belong to the Immune category, suggesting similar primary applications.
- Enfuvirtide has stronger research evidence (FDA Approved) compared to LL-37 (Human Trials).
Detailed Comparison
| Attribute | LL-37 | Enfuvirtide |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 carries a net positive charge and has a water-loving and fat-loving (amphipathic) structure, which lets it home in on the negatively charged membranes of bacteria and physically punch holes in them. But killing microbes directly is only half the job. It also acts as a signaling molecule: it neutralizes bacterial toxin LPS, calms or tunes the inflammatory response, recruits immune cells to wounds and infection sites, and helps skin re-grow and close over injuries. It is produced by skin, gut, lung, and other epithelial cells, plus immune cells like neutrophils. This dual role, direct antimicrobial plus immune coordinator, is why it is described as a multifunctional host-defense peptide. | HIV gets into a cell using a surface protein called gp41, which works like a folding grappling hook. Two stretches of that protein, called heptad repeat 1 and heptad repeat 2, snap together to pull the virus and the cell membrane close enough to fuse. Enfuvirtide is a copy of the HR2 stretch, so it slides in and binds HR1 first, jamming the hinge before it can collapse. With the hinge stuck open, the membranes never fuse and the virus is locked outside the cell. Because it acts on the outside of the cell, it works against HIV that is already resistant to drugs targeting the virus's internal machinery. |
| Common Dosing | 100-200 mcg daily Once daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection or topical | Subcutaneous injection twice daily |
| Typical Duration | Variable by protocol | Ongoing as part of HIV regimen |
| Best Time to Take | Morning | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The basic biology of LL-37 is well established across many peer-reviewed studies. Its broad antimicrobial activity, membrane-disrupting mechanism, and tissue distribution are documented in reviews such as those in the Journal of Leukocyte Biology and PMC-indexed updates on how it limits the spread of local infection. Research has also explored more speculative directions: LL-37 and engineered mimics have shown anticancer activity in laboratory models, and it has been studied as a possible host-defense factor against Helicobacter pylori in the stomach and against pathogens on the surface of the eye. The important honesty point is that almost all of this is mechanistic and preclinical. LL-37 is firmly proven as a natural part of human immunity, but as a deliberately administered therapy it has not cleared large human clinical trials, and its dual nature means it can also drive inflammation in some disease states. So: rock-solid as biology, still experimental as a treatment. | This is one of the better-evidenced antiretrovirals, with real randomized human trials behind it. The pivotal TORO 1 and TORO 2 phase 3 trials, published in the New England Journal of Medicine in 2003, enrolled heavily treatment-experienced patients and showed that adding enfuvirtide to an optimized background regimen roughly doubled the drop in viral load compared with the background regimen alone, with mean HIV RNA reductions on the order of 1.5 log10 copies per mL. Earlier dose-ranging work documented its subcutaneous pharmacokinetics and antiviral activity in HIV-infected adults. The main real-world drawbacks are practical, not theoretical: nearly all patients get injection-site reactions, and twice-daily injections are a burden, which is why newer oral salvage options have largely displaced it. Resistance does develop, usually through mutations in the gp41 HR1 region, so it is always used as part of a combination regimen. It remains an approved drug rather than a speculative peptide, but it is now a niche, last-resort option. |
Frequently Asked Questions: LL-37 vs Enfuvirtide
What is the difference between LL-37 and Enfuvirtide?
LL-37 is a immune peptide that ll-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hcap-18. it is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. this is mainstream, heavily studied human biology, not a fringe research peptide, though ll-37 itself is not an approved drug. Enfuvirtide is a immune peptide that enfuvirtide (brand name fuzeon, originally t-20) is a 36-amino-acid synthetic peptide and the first hiv fusion inhibitor, fda-approved in march 2003. it is a genuine prescription antiretroviral, not a research-only compound, and it is given as a twice-daily subcutaneous injection. its job is narrow but important: it blocks hiv from entering a host cell in the first place, and it is reserved for people whose virus has stopped responding to other drugs. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or Enfuvirtide?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while Enfuvirtide is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and Enfuvirtide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and Enfuvirtide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.